Join
Live feed
·
PRReleasevia Quantisnow
KalVista Pharmaceuticals Inc. logo

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

ByQuantisnow·Wall Street's wire, on your screen.
KALV· KalVista Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KALV (KalVista Pharmaceuticals Inc.) and more on Quantisnow.